- Home
- SYNX vs NEUP Comparison
SYNX vs NEUP Comparison
Compare SYNX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- NEUP
- Stock Information
- Founded
- SYNX 2005
- NEUP 1996
- Country
- SYNX Israel
- NEUP United States
- Employees
- SYNX N/A
- NEUP N/A
- Industry
- SYNX
- NEUP
- Sector
- SYNX
- NEUP
- Exchange
- SYNX Nasdaq
- NEUP Nasdaq
- Market Cap
- SYNX 11.3M
- NEUP 12.7M
- IPO Year
- SYNX 2024
- NEUP N/A
- Fundamental
- Price
- SYNX $1.60
- NEUP $10.07
- Analyst Decision
- SYNX
- NEUP Strong Buy
- Analyst Count
- SYNX 0
- NEUP 2
- Target Price
- SYNX N/A
- NEUP $28.00
- AVG Volume (30 Days)
- SYNX 145.2K
- NEUP 83.7K
- Earning Date
- SYNX 10-02-2025
- NEUP 11-15-2025
- Dividend Yield
- SYNX N/A
- NEUP N/A
- EPS Growth
- SYNX N/A
- NEUP N/A
- EPS
- SYNX N/A
- NEUP 0.00
- Revenue
- SYNX $9,094,000.00
- NEUP $15,662,715.00
- Revenue This Year
- SYNX $32.35
- NEUP N/A
- Revenue Next Year
- SYNX N/A
- NEUP N/A
- P/E Ratio
- SYNX N/A
- NEUP $6,374.34
- Revenue Growth
- SYNX 19.14
- NEUP N/A
- 52 Week Low
- SYNX $1.41
- NEUP $2.90
- 52 Week High
- SYNX $6.49
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- SYNX 46.87
- NEUP 46.18
- Support Level
- SYNX $1.54
- NEUP $11.42
- Resistance Level
- SYNX $1.76
- NEUP $15.14
- Average True Range (ATR)
- SYNX 0.17
- NEUP 1.58
- MACD
- SYNX 0.00
- NEUP -0.33
- Stochastic Oscillator
- SYNX 25.68
- NEUP 3.80
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.